Recent work on immunotherapy in DSRCT has therefore focused on identifying and developing new targets for antibody-based treatments including 1) testing previously identified DSRCT immunotherapy targets such as B7-H3 in clinical trials, 2) investigating repurposed immunotherapy targets from other cancer types in DSRCT xenograft models, and 3) identifying new, more specific DSRCT immunotherapy targets. This evidence concerns the gene CD276 and cancer.